Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RemeGen
Biotech
Vor pays RemeGen $10M for long-acting autoimmune drug successor
Vor Bio is paying RemeGen $10 million upfront to add a long-acting autoimmune drug candidate to its BAFF/APRIL pipeline.
Nick Paul Taylor
Nov 12, 2026 10:16am
AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF race
Jan 12, 2026 11:00am
RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal
Aug 19, 2025 7:18am
Fierce Pharma
Vor Bio's surprise $4B revival deal splits investor reactions
Jun 26, 2025 10:55am
RemeGen grabs one of the world's largest ever biotech IPOs
Nov 9, 2020 7:58am
